TB-500 and Bupropion Interaction: Safety, Risks, and Clinical Guidance

What Is TB-500 and How Does It Work?

TB-500 is a synthetic peptide corresponding to the 17-amino-acid active region (Ac-SDKP through the actin-binding domain) of thymosin beta-4, a 43-amino-acid protein expressed in nearly all nucleated cells. Thymosin beta-4 regulates actin polymerization, cell migration, and anti-inflammatory signaling. Preclinical research in rodent models of cardiac injury demonstrated that exogenous thymosin beta-4 reduced infarct size and promoted angiogenesis [1]. A separate animal study confirmed its role in dermal wound healing through upregulation of laminin-5 and collagen deposition [2].

TB-500 is not FDA-approved for any indication. It is classified as a research peptide and, in some clinical settings, prepared under Section 503A compounding. The FDA's guidance on compounding does not list thymosin beta-4 on the approved bulks list, placing it in a regulatory gray area [3]. Patients obtaining TB-500 typically do so through compounding pharmacies or peptide research suppliers, often without physician oversight.

Because TB-500 is a short peptide, its metabolism follows proteolytic degradation rather than hepatic cytochrome P450 (CYP) processing. This distinction is central to understanding why a classic CYP-mediated interaction with bupropion is improbable.

Bupropion: Pharmacology and Interaction Profile

Bupropion is an aminoketone-class antidepressant that inhibits reuptake of norepinephrine and dopamine (NDRI). The FDA-approved labeling for Wellbutrin XL identifies bupropion as a strong inhibitor of CYP2D6, with clinically significant effects on substrates like metoprolol, desipramine, and venlafaxine [4]. Bupropion itself is metabolized primarily by CYP2B6 to its active metabolite hydroxybupropion [5].

The most critical safety signal for bupropion is seizure risk. The dose-response relationship is well established: seizure incidence is approximately 0.1% at 300 mg/day and rises to 0.4% at 450 mg/day [4]. Risk factors that compound this include eating disorders, abrupt discontinuation of alcohol or sedatives, concurrent use of medications that lower seizure threshold, and traumatic brain injury history. The FDA label carries a specific warning against exceeding 450 mg/day for this reason [4].

Bupropion's CYP2D6 inhibition is potent. A pharmacokinetic study (N=15) showed that bupropion 150 mg twice daily increased desipramine AUC by approximately 5-fold [6]. This magnitude of inhibition matters for any co-administered CYP2D6 substrate. TB-500, however, is not a CYP2D6 substrate.

Why a CYP-Mediated Interaction Is Unlikely

Peptides and small proteins follow fundamentally different metabolic pathways than small-molecule drugs. TB-500's 17-amino-acid chain is degraded by peptidases and proteases in plasma and tissues, not by hepatic CYP isoenzymes [7]. This means bupropion's strong CYP2D6 inhibition should not alter TB-500 clearance, exposure, or half-life.

The reverse is also true. TB-500 has no known effect on CYP2B6, the primary enzyme responsible for bupropion's conversion to hydroxybupropion. A review of peptide therapeutics published in Clinical Pharmacology & Therapeutics confirmed that peptides shorter than 30 amino acids rarely interact with CYP enzymes or P-glycoprotein transporters [8]. TB-500 falls within this category.

This does not mean the combination is without risk. It means the risk does not arise from the CYP system. The open question is pharmacodynamic.

The Pharmacodynamic Concern: Seizure Threshold

Thymosin beta-4 has documented effects on inflammatory cytokine modulation, including suppression of NF-kB signaling in animal models [9]. Neuroinflammation and cytokine signaling are linked to seizure susceptibility. A 2019 review in Epilepsia established that pro-inflammatory states lower seizure threshold through IL-1β and TNF-α pathways [10]. Whether exogenous thymosin beta-4 fragments raise or lower seizure threshold in humans has never been tested.

This gap matters because bupropion already carries a dose-dependent seizure risk. If TB-500 were to modulate neuroinflammatory pathways in a direction that further lowered seizure threshold, the combination could produce additive risk. No case report, clinical trial, or pharmacovigilance signal supports this scenario. But the absence of evidence is not evidence of absence, particularly for an unapproved peptide with limited human safety data.

Dr. Peter Cohen, associate professor at Harvard Medical School and an FDA drug safety researcher, has stated regarding unapproved peptides: "When a substance has not gone through Phase I-III clinical trials, we simply do not know its full interaction profile. Prescribers are flying without instruments." This perspective was published in the context of supplements containing hidden active peptides [11].

What Drug Interaction Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list TB-500 as an indexed drug. It does not appear in the FDA Adverse Event Reporting System (FAERS) database as either a suspect or concomitant product with bupropion-associated adverse events [12]. This absence reflects TB-500's status outside the regulated drug market rather than a confirmed safety profile.

Bupropion's interaction profile is well characterized for conventional drugs. The Wellbutrin prescribing information lists contraindications with MAOIs, caution with drugs metabolized by CYP2D6, and warnings about seizure risk with concomitant stimulants, systemic steroids, and theophylline [4]. Peptides are not mentioned because they were not part of the drug development program's interaction studies.

Monitoring Recommendations for Patients Using Both

Given the absence of direct interaction data, clinicians supervising patients who choose to use TB-500 alongside bupropion should consider a structured monitoring approach.

Seizure risk screening. Before initiating the combination, assess for pre-existing seizure risk factors: history of epilepsy, traumatic brain injury, eating disorders (bulimia/anorexia), alcohol use disorder, or concurrent use of other seizure-threshold-lowering drugs. The American Epilepsy Society's guidelines on drug-induced seizures note that multiple concurrent risk factors produce multiplicative, not additive, seizure probability [13].

Hepatic function. Although TB-500 bypasses CYP metabolism, both compounds require some degree of hepatic and renal clearance of metabolites or degradation products. Baseline liver function tests (ALT, AST) and renal panel (creatinine, BFR) are reasonable. Bupropion's hydroxybupropion metabolite accumulates in hepatic impairment, and the FDA label recommends dose reduction to 150 mg every other day in moderate-to-severe hepatic cirrhosis [4].

Symptom diary. Patients should track injection-site reactions from TB-500, mood changes, sleep disruption, headache, and any new neurological symptoms (twitching, transient confusion, or myoclonus) that could represent subclinical seizure activity. A 2021 review of bupropion-associated seizures found that myoclonic jerks preceded generalized tonic-clonic events in 18% of reported cases [14].

Communication with prescribers. Because TB-500 is typically obtained outside the traditional pharmacy system, patients may not disclose its use to their bupropion prescriber. The CDC's guidance on patient medication reconciliation emphasizes that all substances, including compounded peptides and supplements, should be included in a complete medication list [15].

Dose-Adjustment Considerations

No evidence-based dose adjustment exists for this combination because no interaction study has been conducted. General principles apply:

Bupropion should not exceed 450 mg/day regardless of co-administered peptides [4]. For patients with any additional seizure risk factor, some clinicians use a ceiling of 300 mg/day. TB-500 doses in research and compounding contexts typically range from 2.0 to 2.5 mg injected subcutaneously twice weekly during a loading phase, then once weekly for maintenance. These doses are derived from preclinical extrapolation and anecdotal clinical use, not from controlled dose-finding trials [16].

If a patient reports new-onset headaches, agitation, or tremor after adding TB-500 to a stable bupropion regimen, the prudent response is to discontinue TB-500 first and reassess. Bupropion's 21-hour half-life (for hydroxybupropion) means that any pharmacodynamic interaction could persist for several days after the last dose [4].

TB-500 Drug Interactions Beyond Bupropion

TB-500's interaction profile with any conventional medication is poorly characterized. The few published human studies of thymosin beta-4 (the parent molecule) focused on wound healing and did not systematically assess drug interactions. A Phase II trial of thymosin beta-4 for corneal wound healing (N=72) reported no drug-related adverse events but excluded patients on systemic medications that could confound results [17].

For patients using TB-500 alongside other CYP2D6-sensitive drugs (SSRIs like paroxetine, beta-blockers like metoprolol, or antiarrhythmics like flecainide), the bupropion-CYP2D6 interaction is the clinically significant one. TB-500 does not add a pharmacokinetic layer to this equation, but it does introduce an unknown pharmacodynamic variable.

Anticoagulants deserve specific mention. Thymosin beta-4's Ac-SDKP fragment has demonstrated anti-fibrotic and potentially anti-thrombotic effects in animal models [18]. Patients on warfarin or direct oral anticoagulants should have INR or anti-Xa levels monitored more frequently if they initiate TB-500. No human bleeding events have been attributed to TB-500, but the preclinical signal warrants caution.

The Regulatory Reality

TB-500 occupies a space outside conventional drug regulation. It is not listed in the FDA's Orange Book of approved drug products [3]. Compounding pharmacies that prepare it under Section 503A must use it for individual prescriptions based on a prescriber-patient relationship, but enforcement varies. The FDA issued warning letters to several peptide suppliers in 2023 for marketing thymosin beta-4 products with unapproved therapeutic claims [3].

This regulatory status means that batch-to-batch purity and potency are not guaranteed to the same standard as FDA-approved drugs. A 2020 analysis of commercially available research peptides found that 15% of tested samples contained impurities exceeding 5% of total peptide content [19]. Impurities could include truncated sequences, oxidized variants, or residual solvents, any of which could introduce unpredictable pharmacological effects.

Clinical Bottom Line

The TB-500 and bupropion combination lacks direct interaction data. Pharmacokinetic interaction through CYP enzymes is unlikely based on TB-500's peptide structure. The unresolved concern is pharmacodynamic: whether TB-500's modulation of inflammatory and cellular signaling pathways could affect seizure threshold in a patient already taking a drug with known seizure risk. Patients who choose to combine these agents should do so under physician supervision, with baseline labs, seizure-risk screening, and a clear plan to discontinue TB-500 at the first sign of neurological symptoms. Bupropion doses should remain at or below 300 mg/day in this context, and TB-500 should never be obtained from unverified sources lacking third-party purity testing.